drug delivery platform rnai mauro ferrari
-
"Any effective delivery technology method must be able to overcome all the bio-barriers between administration and the target cell." - Dr. Mauro Ferrari
-
Our bodies' own defense mechanisms prevent all but a small number of therapeutic molecules from reaching their site of action.
-
Leonardo has demonstrated a manufacturing process which we believe will scale economically.
arrowhead research drug development
pharmaceuticals chemotherapy nanotech
A Unique Drug Delivery System
Leo is the exclusive provider of a revolutionary multistage drug delivery platform (MSV™) focused on the treatment of metastatic cancers. The first stage consists of a silicon nanoparticle that is rationally designed to circumvent the multiple biological barriers between the injection point and the cancer cells. These non-toxic silicon particles can carry a very high concentration of second stage delivery particles, such as liposomes, micelles, or polymeric delivery constructs which are loaded with active drug compounds and associated delivery enhancement materials.Leonardo plans to generate revenue through the development of a series of breakthrough oncology products, and through partnerships with pharmaceutical companies where improvement in tolerability and efficacy of their drugs is desired. Leonardo's multi-stage vector (MSV™) silicon particle approach is unique in the industry and offers several significant competitive advantages.
Opportunity
Most anti-cancer drugs are untargeted cytotoxins. It is estimated that only 1 in 100,000 drug molecules actually reaches its intended target—the cancer cell. The remainder of the drug molecules are degraded or spread throughout the body where they cause serious side effects including nausea, anemia, fatigue and more.Roughly 40% of new anti-cancer compounds fail to enter human clinical trials due to toxicity and solubility problems. Many compounds tested in humans ultimately fail to gain FDA approval due to toxic side effects. The pharmaceutical industry has expended considerable amounts of time and money seeking to solve this problem. Leonardo is positioned to improve the performance of drugs already on the market as well as enable new therapeutics, such as RNAi.
News
11/28/2011
Leonardo Biosystems and NanoMedical Systems Sign Collaboration Deal for Manufacturing Scale Up of Leonardo's Drug Delivery Nanoparticles. Read
Leonardo Biosystems and NanoMedical Systems Sign Collaboration Deal for Manufacturing Scale Up of Leonardo's Drug Delivery Nanoparticles. Read
11/14/2011
Leonardo Biosystems Receives Second $1.25 Million Investment from the Texas Emerging Technology Fund. Read
Leonardo Biosystems Receives Second $1.25 Million Investment from the Texas Emerging Technology Fund. Read
09/17/2011
Mauro Ferrari Honored by the Controlled Release Society. Read
Mauro Ferrari Honored by the Controlled Release Society. Read
08/12/10
Dr. Mauro Ferrari joins The Methodist Hospital Research Institute as President and CEO. Read
Dr. Mauro Ferrari joins The Methodist Hospital Research Institute as President and CEO. Read